中国医药
中國醫藥
중국의약
CHINA MEDICINE
2010年
4期
333-334
,共2页
欧阳石%程涛%李灼亮%刘树人%肖必%佟明华%余宙耀%孔祥平
歐暘石%程濤%李灼亮%劉樹人%肖必%佟明華%餘宙耀%孔祥平
구양석%정도%리작량%류수인%초필%동명화%여주요%공상평
肝硬化%骨髓干细胞%移植
肝硬化%骨髓榦細胞%移植
간경화%골수간세포%이식
Hepatic cirrhosis%Bone marrow stem cell%Transplantation
目的 探讨自体骨髓干细胞(BMSC)移植对肝硬化失代偿期患者的治疗作用.方法 23例肝硬化失代偿期患者无菌抽取骨髓60-100 ml,分离纯化BMSC,然后经肝动脉导管注入肝脏.术前术后定期检测肝功能,并观察同期的症状体征和不良反应情况.结果 与术前比较,术后1周内所有血清学指标均无明显改变;术后1个月,白蛋白为(31.44±2.08)g/L vs(27.63±2.04)g/L(P<0.01);谷丙转氨酶为(58.70±25.87)U/L vs(67.13±27.78)U/L(P<0.01);总胆红素、血小板等指标均无明显变化(P>0.05).移植后大多数患者症状改善明显,移植后1个月内腹水减轻12例(52%),食欲改善10例(43%),体力好转11例(47.8%),腹胀减轻9例(39.1%),睡眠改善12例(52.1%).结论 自体骨髓干细胞肝内移植治疗失代偿期肝硬化是一种安全的治疗措施,对失代偿期的肝脏可起到一定支持作用.
目的 探討自體骨髓榦細胞(BMSC)移植對肝硬化失代償期患者的治療作用.方法 23例肝硬化失代償期患者無菌抽取骨髓60-100 ml,分離純化BMSC,然後經肝動脈導管註入肝髒.術前術後定期檢測肝功能,併觀察同期的癥狀體徵和不良反應情況.結果 與術前比較,術後1週內所有血清學指標均無明顯改變;術後1箇月,白蛋白為(31.44±2.08)g/L vs(27.63±2.04)g/L(P<0.01);穀丙轉氨酶為(58.70±25.87)U/L vs(67.13±27.78)U/L(P<0.01);總膽紅素、血小闆等指標均無明顯變化(P>0.05).移植後大多數患者癥狀改善明顯,移植後1箇月內腹水減輕12例(52%),食欲改善10例(43%),體力好轉11例(47.8%),腹脹減輕9例(39.1%),睡眠改善12例(52.1%).結論 自體骨髓榦細胞肝內移植治療失代償期肝硬化是一種安全的治療措施,對失代償期的肝髒可起到一定支持作用.
목적 탐토자체골수간세포(BMSC)이식대간경화실대상기환자적치료작용.방법 23례간경화실대상기환자무균추취골수60-100 ml,분리순화BMSC,연후경간동맥도관주입간장.술전술후정기검측간공능,병관찰동기적증상체정화불량반응정황.결과 여술전비교,술후1주내소유혈청학지표균무명현개변;술후1개월,백단백위(31.44±2.08)g/L vs(27.63±2.04)g/L(P<0.01);곡병전안매위(58.70±25.87)U/L vs(67.13±27.78)U/L(P<0.01);총담홍소、혈소판등지표균무명현변화(P>0.05).이식후대다수환자증상개선명현,이식후1개월내복수감경12례(52%),식욕개선10례(43%),체력호전11례(47.8%),복창감경9례(39.1%),수면개선12례(52.1%).결론 자체골수간세포간내이식치료실대상기간경화시일충안전적치료조시,대실대상기적간장가기도일정지지작용.
Objective To evaluate the effect of autologous bone marrow-derived stem cell (BMSCs) trans-plantation in the treatment of decomponsated hepatic cirrhosis. Methods Bone marrow was harvested (60~100 ml) from 23 patients in the transplantation group. The BMSCs were isolated and infused into liver of patients via he-patic artery. At different time points after the transplantation,the patients'liver function and the quantity of blood platelet (PLT)were evaluated. Results All the serum biochemical indexes remained stable 1 week after the trans-plantation. After 4 weeks, albumin level increased significantly in comparison with the preoperative level(P<0.01) and ALT was significantly lowered (P<0.01), but total hilirubin and the quantity of PLT remained unchanged(P> 0.05). 4 weeks after transplantation, ascites decreased in 12 cases(52%), appetite improved in 10 cases(43%) and abdomen distention ameliorated in 9 cases (39.1%). No adverse events developed in 23 patients with bone marrow stem cells transplantation. Conclusion BMSCs transplantation can improve the liver function of patients with decompensated liver cirrhosis and showes good safety and effectiveness.